Waldenström Macroglobulinemia Market to Gain Momentum During the Forecast Period (2026-2036) Due to Launch of Novel Drug Classes Including BTK Degraders, Non-covalent BTKi, BCL-2 Inhibitors, and Targeted Radiotherapeutics | DelveInsight

BTK DegradersNon-covalent BTKiBCL-2 InhibitorsPositive

AI Analysis

Summary

DelveInsight market analysis projects steady growth in the Waldenström Macroglobulinemia market from 2026-2036, driven by novel therapeutics including BTK degraders, non-covalent BTKi, BCL-2 inhibitors, and targeted radiotherapeutics, along with improved disease awareness and diagnostics.

Importance:2/10

Sentiment:

0.50

Waldenström Macroglobulinemiamarket analysisBTK inhibitorsnovel drug classesforecast

Read the original article

Published by PR Newswire Biotech on September 9, 2026 2:31 PM

Read Original